State of Tennessee Treasury Department lessened its holdings in shares of Anika Therapeutics Inc (NASDAQ:ANIK) by 5.3% during the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 8,475 shares of the biotechnology company’s stock after selling 471 shares during the quarter. State of Tennessee Treasury Department owned approximately 0.06% of Anika Therapeutics worth $319,000 at the end of the most recent quarter.
Other large investors have also added to or reduced their stakes in the company. Nisa Investment Advisors LLC raised its stake in shares of Anika Therapeutics by 12.7% in the second quarter. Nisa Investment Advisors LLC now owns 2,974 shares of the biotechnology company’s stock worth $112,000 after acquiring an additional 334 shares during the last quarter. Comerica Bank boosted its holdings in shares of Anika Therapeutics by 3.0% during the first quarter. Comerica Bank now owns 13,793 shares of the biotechnology company’s stock worth $461,000 after acquiring an additional 401 shares during the period. Thrivent Financial for Lutherans grew its holdings in shares of Anika Therapeutics by 5.3% during the 1st quarter. Thrivent Financial for Lutherans now owns 11,959 shares of the biotechnology company’s stock worth $346,000 after purchasing an additional 597 shares in the last quarter. American International Group Inc. increased its position in shares of Anika Therapeutics by 6.5% in the second quarter. American International Group Inc. now owns 9,900 shares of the biotechnology company’s stock worth $374,000 after purchasing an additional 604 shares during the period. Finally, California Public Employees Retirement System increased its position in shares of Anika Therapeutics by 2.1% in the second quarter. California Public Employees Retirement System now owns 30,939 shares of the biotechnology company’s stock worth $1,167,000 after purchasing an additional 635 shares during the period. 97.24% of the stock is currently owned by institutional investors.
Anika Therapeutics stock opened at $35.75 on Wednesday. Anika Therapeutics Inc has a fifty-two week low of $22.01 and a fifty-two week high of $75.71. The stock has a market cap of $515.16 million, a PE ratio of 22.52, a price-to-earnings-growth ratio of 4.12 and a beta of 1.11. The firm’s 50-day simple moving average is $36.32 and its 200 day simple moving average is $34.33. The company has a debt-to-equity ratio of 0.17, a quick ratio of 6.26 and a current ratio of 7.93.
Anika Therapeutics (NASDAQ:ANIK) last released its quarterly earnings results on Thursday, July 30th. The biotechnology company reported ($0.54) earnings per share for the quarter, missing the consensus estimate of ($0.21) by ($0.33). The firm had revenue of $30.68 million for the quarter, compared to analysts’ expectations of $16.73 million. Anika Therapeutics had a return on equity of 8.05% and a net margin of 7.17%. As a group, analysts predict that Anika Therapeutics Inc will post 0.88 EPS for the current fiscal year.
ANIK has been the topic of several research reports. Zacks Investment Research upgraded Anika Therapeutics from a “hold” rating to a “buy” rating and set a $40.00 price target on the stock in a report on Tuesday, August 4th. BidaskClub raised Anika Therapeutics from a “sell” rating to a “hold” rating in a research note on Thursday, August 20th. One research analyst has rated the stock with a sell rating, three have given a hold rating, two have assigned a buy rating and one has assigned a strong buy rating to the company. Anika Therapeutics has an average rating of “Hold” and a consensus price target of $51.00.
In related news, EVP James Loerop sold 1,244 shares of the company’s stock in a transaction that occurred on Thursday, July 9th. The shares were sold at an average price of $35.15, for a total transaction of $43,726.60. Following the sale, the executive vice president now owns 3,000 shares of the company’s stock, valued at approximately $105,450. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders own 2.53% of the company’s stock.
Anika Therapeutics Company Profile
Anika Therapeutics, Inc, together with its subsidiaries, provides orthopedic medicines for patients with degenerative orthopedic diseases and traumatic conditions in the United States and internationally. The company develops, manufactures, and commercializes therapeutic products based on its proprietary hyaluronic acid (HA) technology.
Recommended Story: Pattern Day Trader – What is the PDT Rule?
Want to see what other hedge funds are holding ANIK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Anika Therapeutics Inc (NASDAQ:ANIK).
Receive News & Ratings for Anika Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Anika Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.